Tolerance, immunosuppression, and immune modulation: impacts on lung allograft survival.
Journal
Current opinion in organ transplantation
ISSN: 1531-7013
Titre abrégé: Curr Opin Organ Transplant
Pays: United States
ID NLM: 9717388
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
pubmed:
31
3
2021
medline:
30
9
2021
entrez:
30
3
2021
Statut:
ppublish
Résumé
Immune responses following lung transplantation continue to result in high rates of allograft failure and rejection, and current immunosuppression does not address the unique immunologic properties of the lung. Here, we review recent studies on lung allograft tolerance and alloimmunity and discuss implications for immunosuppression. Processes governing tolerance and alloimmunity in lung allografts differ from other solid organs. Recent studies have suggested that allorecognition is regulated at the level of the lung graft. Furthermore, certain cell populations essential for lung allograft tolerance may facilitate rejection in other organs. Induction of lung allograft tolerance is associated with the formation of tertiary lymphoid organs, which are enriched in regulatory T cells and play an important role in preventing rejection. Recent discoveries regarding alloactivation and the regulation of tolerance following lung transplantation have introduced exciting potential avenues for the development of lung-specific immunosuppression.
Identifiants
pubmed: 33782247
doi: 10.1097/MOT.0000000000000871
pii: 00075200-202106000-00011
pmc: PMC8523032
mid: NIHMS1684448
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
328-332Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL151078
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI116501
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL094601
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL138466
Pays : United States
Organisme : BLRD VA
ID : I01 BX002730
Pays : United States
Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Hardy JD, Webb WR, Dalton ML ET-AL>. Lung homotransplantation in man. JAMA 1963; 186:1065–1074.
Khush KK, Potena L, Cherikh WS, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 37th adult heart transplantation report-2020; focus on deceased donor characteristics. J Heart Lung Transplant 2020; 39:1003–1015.
Balsara KR, Krupnick AS, Bell JM, et al. A single-center experience of 1500 lung transplant patients. J Thorac Cardiovasc Surg 2018; 156:894–905.
Gelman AE, Li W, Richardson SB, et al. Cutting edge: acute lung allograft rejection is independent of secondary lymphoid organs. J Immunol 2009; 182:3969–3973.
Gelman AE, Okazaki M, Sugimoto S, et al. CCR2 regulates monocyte recruitment as well as CD4 T1 allorecognition after lung transplantation. Am J Transplant 2010; 10:1189–1199.
Krupnick AS, Lin X, Li W, et al. Central memory CD8+ T lymphocytes mediate lung allograft acceptance. J Clin Investig 2014; 124:1130–1143.
Li W, Bribriesco AC, Nava RG, et al. Lung transplant acceptance is facilitated by early events in the graft and is associated with lymphoid neogenesis. Mucosal Immunol 2012; 5:544–554.
Lakkis FG, Arakelov A, Konieczny BT ET-AL>. Immunologic ‘ignorance’ of vascularized organ transplants in the absence of secondary lymphoid tissue. Nat Med 2000; 6:686–688.
Zhang N, Schröppel B, Lal G, et al. Regulatory T cells sequentially migrate from inflamed tissues to draining lymph nodes to suppress the alloimmune response. Immunity 2009; 30:458–469.
Todd JL, Wang X, Sugimoto S, et al. Hyaluronan contributes to bronchiolitis obliterans syndrome and stimulates lung allograft rejection through activation of innate immunity. Am J Resp Crit Care Med 2014; 189:556–566.
Tanaka S, Gauthier JM, Terada Y, et al. Bacterial products in donor airways prevent the induction of lung transplant tolerance. Am J Transplant 2021; 21:353–361.
Kreisel D, Sugimoto S, Zhu J, et al. Emergency granulopoiesis promotes neutrophil-dendritic cell encounters that prevent mouse lung allograft acceptance. Blood 2011; 118:6172–6182.
Christie JD, Kotloff RM, Ahya VN, et al. The effect of primary graft dysfunction on survival after lung transplantation. Am J Resp Crit Care Med 2005; 171:1312–1316.
Kim H, Zamel R, Bai XH, et al. Ischemia-reperfusion induces death receptor-independent necroptosis via calpain- STAT3 activation in a lung transplant setting. Am J Physiol Lung Cell Mol Physiol 2018; 315:L595–608.
Wang X, O’Brien ME, Yu J, et al. Prolonged cold ischemia induces necroptotic cell death in ischemia-reperfusion injury and contributes to primary graft dysfunction after lung transplantation. Am J Resp Cell Mol Biol 2019; 61:244–256.
Zheng Z, Chiu S, Akbarpour M, et al. Donor pulmonary intravascular nonclassical monocytes recruit recipient neutrophils and mediate primary lung allograft dysfunction. Sci Transl Med 2017; 9:eaal4508.
Hsiao HM, Fernandez R, Tanaka S, et al. Spleen-derived classical monocytes mediate lung ischemia-reperfusion injury through IL-1β. J Clin Investig 2018; 128:2833–2847.
Yamamoto S, Nava RG, Zhu J, et al. Cutting edge: Pseudomonas aeruginosa abolishes established lung transplant tolerance by stimulating B7 expression on neutrophils. J Immunol 2012; 189:4221–4225.
Weigt SS, Elashoff RM, Keane MP, et al. Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality postlung transplantation. Am J Transplant 2008; 8:1512–1522.
Botha P, Archer L, Anderson RL, et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation 2008; 85:771–774.
Aguilar PR, Carpenter D, Ritter J, et al. The role of C4d deposition in the diagnosis of antibody-mediated rejection after lung transplantation. Am J Transplant 2018; 18:936–944.
Jaramillo A, Smith CR, Maruyama T, et al. Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome. Hum Immunol 2003; 64:521–529.
Li W, Gauthier JM, Higashikubo R, et al. Bronchus-associated lymphoid tissue-resident Foxp3 + T lymphocytes prevent antibody-mediated lung rejection. J Clin Investig 2019; 2:556–568.
Onyema OO, Guo Y, Wang Q, et al. Eosinophils promote inducible NOS-mediated lung allograft acceptance. JCI Insight 2017; 2:e96455.
Onyema OO, Guo Y, Mahgoub B, et al. Eosinophils downregulate lung alloimmunity by decreasing TCR signal transduction. JCI Insight 2019; 4:e128241.
Baddoura FK, Nasr IW, Wrobel B, et al. Lymphoid neogenesis in murine cardiac allografts undergoing chronic rejection. Am J Transplant 2005; 5:510–516.
Thaunat O, Field AC, Dai J, et al. Lymphoid neogenesis in chronic rejection: evidence for a local humoral alloimmune response. Proc Natl Acad Sci USA 2005; 102:14723–14728.
Li W, Gauthier JM, Tong AY, et al. Lymphatic drainage from bronchus-associated lymphoid tissue in tolerant lung allografts promotes peripheral tolerance. J Clin Investig 2020; 12:6718–6727.
Tanaka S, Gauthier JM, Fuchs A, et al. IL-22 is required for the induction of bronchus-associated lymphoid tissue in tolerant lung allografts. Am J Transplant 2020; 5:1251–1261.
Gregson AL, Hoji A, Saggar R, et al. Bronchoalveolar immunologic profile of acute human lung transplant allograft rejection. Transplantation 2008; 85:1056–1059.
Ius F, Salman J, Knoefel AK, et al. Increased frequency of CD4 + CD25 high CD127 low T cells early after lung transplant is associated with improved graft survival - a retrospective study. Transpl Int 2020; 33:503–506.
Cui Y, Liu K, Monzon-Medina ME, et al. Therapeutic lymphangiogenesis ameliorates established acute lung allograft rejection. J Clin Investig 2015; 125:4255–4268.
Miroux C, Morales O, Ghazal K, et al. In vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function. Transplantation 2012; 94:123–131.
Dusting GJ, Akita K, Hickey H, et al. Cyclosporin A and tacrolimus (FK506) suppress expression of inducible nitric oxide synthase in vitro by different mechanisms. Br J Pharmacol 1999; 128:337–344.
Demirkiran A, Sewgobind V, van der Weijde J, et al. Conversion from calcineurin inhibitor to mycophenolate mofetil-based immunosuppression changes the frequency and phenotype of CD4 + FOXP3 + regulatory T cells. Transplantation 2009; 87:1062–1068.
He X, Smeets RL, Koenen HJ, et al. Mycophenolic acid-mediated suppression of human CD4 + T cells: more than mere guanine nucleotide deprivation. Am J Transplant 2011; 11:439–449.
Chen X, Murakami T, Oppenheim JJ, et al. Differential response of murine CD4 + CD25 + and CD4 + CD25 - T cells to dexamethasone-induced cell death. Eur J Immunol 2004; 34:859–869.
Oishi H, Juvet SC, Martinu T, et al. A novel combined ex vivo and in vivo lentiviral interleukin-10 gene delivery strategy at the time of transplantation decreases chronic lung allograft rejection in mice. J Thorac Cardiovasc Surg 2018; 156:1305–1315.
Kreisel D, Lai J, Richardson SB, et al. Polarized alloantigen presentation by airway epithelial cells contributes to direct CD8 + T cell activation in the airway. Am J Respir Cell Mol Biol 2011; 44:749–754.
Haam S, Noda K, Phillips BJ, et al. Cyclosporin A administration during ex vivo lung perfusion preserves lung grafts in rat transplant model. Transplantation 2020; 104:e252–e259.
Emaminia A, LaPar DJ, Zhao Y, et al. Adenosine A2A agonist improves lung function during ex vivo lung perfusion. Ann Thorac Surg 2011; 92:1840–1846.
Sagoo P, Ali N, Garg G, et al. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med 2011; 3:83ra42.
Putnam AL, Safinia N, Medvec A, et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. Am J Transplant 2013; 13:3010–3020.
Rhodes KR, Meyer RA, Wang J, et al. Biomimetic tolerogenic artificial antigen presenting cells for regulatory T cell induction. Acta Biomater 2020; 112:136–148.
Noyan F, Zimmermann K, Hardtke-Wolenski M, et al. Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor. Am J Transplant 2017; 17:917–930.
Skuljec J, Chmielewski M, Happle C, et al. Chimeric antigen receptor-redirected regulatory T cells suppress experimental allergic airway inflammation, a model of asthma. Front Immunol 2017; 8:1–12.
Benazzo A, Worel N, Schwarz S, et al. Outcome of extracorporeal photopheresis as an add-on therapy for antibody-mediated rejection in lung transplant recipients. Transfus Med Hemother 2020; 47:205–213.
Morrell MR, Despotis GJ, Lublin DM, et al. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2010; 29:424–431.
Gatza E, Rogers CE, Clouthier SG, et al. Extracorporeal photopheresis reverses experimental graft-versus-host disease through regulatory T cells. Blood 2008; 112:1515–1521.
Jungraithmayr W, Codarri L, Bouchaud G, et al. Cytokine complex-expanded natural killer cells improve allogeneic lung transplant function via depletion of donor dendritic cells. Am J Respir Crit Care Med 2013; 187:1349–1359.